IDH1 and neoplasm: Several established targets have multiple clinical compounds in later stages of development across a variety of tumor types (e.g., IDO1, IDH1), while many earlier-phase studies are being initiated with first-in-class agents targeting metabolic nodes not yet explored (e.g., IACS-010759, opaganib).